Endra Life Sciences Inc. logo

Endra Life Sciences Inc. (NDRA)

Market Closed
12 Dec, 20:00
NASDAQ (CM) NASDAQ (CM)
$
5. 49
-0.43
-7.26%
$
4.69M Market Cap
- P/E Ratio
0% Div Yield
41,356 Volume
-1.41 Eps
$ 5.92
Previous Close
Day Range
5.28 5.6
Year Range
2.9 11.96
Want to track NDRA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NDRA closed yesterday lower at $5.49, a decrease of 7.26% from Thursday's close, completing a monthly decrease of -4.27% or $0.25. Over the past 12 months, NDRA stock lost -12.3%.
NDRA is not paying dividends to its shareholders.
The last earnings report, released on Nov 21, 2025, exceeded the consensus estimates by 1.95%. On average, the company has surpassed earnings expectations by 0.03%, based on the last three reports.
Endra Life Sciences Inc. has completed 3 stock splits, with the recent split occurring on Nov 07, 2024.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

NDRA Chart

Similar

Alchemy Investments Acquisition Corp 1
$ 0.12
-20.32%
Alchemy Investments Acquisition Corp.
$ 11.4
0%
Neovolta Inc. Warrant
$ 1.3
-7.8%
Laser Photonics Corporation
$ 2.99
+0.34%
Kairous Acquisition Corp. Limited
$ 12.33
0%
What Makes ENDRA Life Sciences (NDRA) a New Strong Buy Stock

What Makes ENDRA Life Sciences (NDRA) a New Strong Buy Stock

ENDRA Life Sciences (NDRA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 10 months ago
ENDRA Life Sciences Inc. (NDRA) Q2 2024 Earnings Call Transcript

ENDRA Life Sciences Inc. (NDRA) Q2 2024 Earnings Call Transcript

ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q2 2024 Earnings Conference Call August 22, 2024 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Alexander Tokman - Acting CEO Ziad Rouag - Head of Regulatory and Clinical Affairs Michael Thornton - Chief Technology Officer Richard Jacroux - CFO Conference Call Participants Edward Woo - Ascendiant Capital Operator Good afternoon, and welcome to the ENDRA Life Sciences Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode.

Seekingalpha | 1 year ago
Why Is ENDRA Life Sciences (NDRA) Stock Up 36% Today?

Why Is ENDRA Life Sciences (NDRA) Stock Up 36% Today?

ENDRA Life Sciences (NASDAQ: NDRA ) stock is up on Monday after the clinical diagnostic ultrasound technology company revealed an investment from S.H.N. Financial Investments Ltd.

Investorplace | 1 year ago

Endra Life Sciences Inc. (NDRA) FAQ

What is the stock price today?

The current price is $5.49.

On which exchange is it traded?

Endra Life Sciences Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is NDRA.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 4.69M.

Has Endra Life Sciences Inc. ever had a stock split?

Endra Life Sciences Inc. had 3 splits and the recent split was on Nov 07, 2024.

Endra Life Sciences Inc. Profile

Professional Services Industry
Industrials Sector
Alexander Y. Tokman CEO
NASDAQ (CM) Exchange
29273B104 CUSIP
US Country
21 Employees
- Last Dividend
7 Nov 2024 Last Split
9 May 2017 IPO Date

Overview

ENDRA Life Sciences Inc. is a pioneering company focused on enhancing the capabilities of clinical diagnostic ultrasound through advanced technology. Based in Ann Arbor, Michigan, and incorporated in 2007, ENDRA Life Sciences strives to revolutionize the way diseases are diagnosed and treated, with a special focus on nonalcoholic fatty liver disease. The company has made significant strides in the field through its collaboration with General Electric Company, showcasing its commitment to integrating cutting-edge research and development into practical medical applications.

Products and Services

ENDRA Life Sciences Inc. offers a range of innovative diagnostic imaging technologies aimed at improving patient care through more accurate and non-invasive diagnostics. These technologies include:

  • Thermo-Acoustic Enhanced Ultrasound Technology: This flagship technology utilizes sound waves that interact with body tissues, organs, and blood. The interaction generates images that can assist in the diagnosis and treatment of various conditions, including nonalcoholic fatty liver disease. This technology stands out for its ability to provide more detailed images compared to traditional ultrasound, offering significant advancements in understanding tissue composition, measuring temperature changes, conducting vascular imaging, and assessing tissue perfusion.
  • Computed Tomography (CT): ENDRA Life Sciences harnesses the power of CT scans to create detailed images of the inside of the body. CT scans are particularly useful in diagnosing cancers, investigating signs of heart disease, and detecting internal bleeding or broken bones. The technology offers a non-invasive way to guide treatment plans and understand the internal workings of the human body in greater detail.
  • Magnetic Resonance Imaging (MRI): MRI is another critical tool in ENDRA’s arsenal, providing detailed images of the body’s organs and tissues using magnetic fields and radio waves. This technology is invaluable for diagnosing a wide range of conditions, from brain and spinal cord injuries to tumors and diseases affecting the joints. Its non-invasive nature and the detailed images it produces make MRI an essential tool in modern medicine.
  • Ultrasound: Beyond its enhanced ultrasound technology, ENDRA also offers traditional ultrasound imaging, a versatile diagnostic method used to capture live images of the internal structures of the body. It is widely used in various medical scenarios, such as monitoring the health of fetuses during pregnancy, diagnosing gallbladder disease, and evaluating other conditions that require visualization of soft tissue structures.

Contact Information

Address: 3600 Green Court
Phone: 734 335 0468